BANNER MEDIA YEAR
2012 Coverage of MRF

ABC News
Ann Romney's MS Revelation: The Trauma of Diagnosis

Biocentury
Myelin Repair Foundation, Endece in MS Deal

Biocentury
ENDECE, Myelin Repair Foundation Deal

Biocentury
Antigen-coupled Peripheral Lymphocytes: Phase I/IIa Data

BioTuesdays
Leading the Fight to Repair Myelin in MS Patients

Businessweek
Speeding Up the Discovery of Drugs

CalBusiness
Finding a Cure

Chemical and Engineering News
The New Scientists

CNN Health
Living with Multiple Sclerosis Means Struggles and Triumphs

CNN iReport
MS Patient Drug Hunter: Helen Solinski

Compromiso Empresarial
Scott Johnson, Cuando el Filantropo es Tambien Paciente y Emprendedor

Drug Discovery & Development
MRF Examining Phase 3 Trial Failures

Drug Discovery & Development
Clinical Trial Examines Myelin Tolerization of the Immune System

Drug Discovery & Development
MRF Joins ENDECE to Develop Treatment for Multiple Sclerosis

Drug Discovery News
Engendering the Collaborative Spirit to Cure MS

Fast Company
A Look Around the Bend on the Health Innovation Highway

FierceBiotech
Analysis: Crusades to Repair Broken Drug R&D One Disease at a Time

Forbes
Translation, Innovation, Regulation: Responding to Biopharma’s Key Challenges

Forbes.com
Ten Lessons on Fighting Disease from Michael J Fox

Forbes.com
The Most Important New Drug of 2012

Genetic Engineering & Biotechnology News
Endece, MRF to Progress Myelin Regeneration Candidates into Clinic

Genetic Engineering & Biotechnology News
MSC-Secreted Factor Key to Impact of Multiple Sclerosis Cell Therapy

Genetic Engineering & Biotechnology News
Filling the Drug Translation Gap

Genetic Engineering & Biotechnology News
Crossing the Valley of Death

Gizmag
Nanoparticle Shows Promise in Treatment of Multiple Sclerosis

Mendel’s Pod
When Drug Discovery Gets Personal

Nature Biotechnology
Patient Power

NBC News—Vitals Blog
New Approach Could Treat MS, Other Autoimmune Diseases

NerdWallet.com
NerdWallet’s Top 6 Healthcare Innovation Nonprofits

Perspectives in Philanthropy
Reforming the Medical Research Enterprise: Breaking Down the Barriers

Pharmaceutical Executive
Today’s Mission Critical: Making Sense of Spending on Clinical Trials

Pharmaceutical Executive
Three Ways to the Future

Pharmaceutical Processing
Research Breakthrough Selectively Represses Immune System

Reuters
Can Portfolio Theory Save Lives?

San Francisco Business Times
One-on-One with UCSF Researcher Jonah Chan

Saratoga News
Saratoga’s Johnson Wins a Research! America Award

SciBx
Micromanaging Tolerance

SF Chronicle
Medical Breakthroughs Come at Slow Pace

Silicon Valley/San Jose Business Journal
Clinical Trial to Target Multiple Sclerosis

The Atlantic
Mission Critical: How Translation-Focused Disease Foundations May Save Medical Research

The Atlantic
Will Patients Bear the Burden for Developing Their Own Treatments

The Burrill Report
Foundations Supply Key Development Funding

The Daily Herald
Career Coach: Collaboration Among Competitors Can Be Useful

The Pink Sheet
Myelin Repair Foundation Teams with Academia to Find Therapies That Can Halt MS

The Scientist
The Profits of Nonprofit

The Scientist
Could Stem Cells Cure MS?

USA Today/Reno Gazette Journal
Parents of Twins with Rare Disease Fight for FDA Approval of Treatment

VentureBeat
Game Designers and Rockefeller Foundation Attack Poverty with Fun

Xconomy
Disease Foundations Play Growing Role in Biotech Business Model

www.myelinrepair.org
18809 Cox Avenue, Suite 190 / Saratoga, CA 95070 / 408.871.2410
©2013 Myelin Repair Foundation. All rights reserved.
WHAT OTHERS ARE SAYING...
A selection of 2012 quotes highlighting MRF’s unique approach to medical research

The Atlantic
Mission Critical: How Translation-Focused Disease Foundations May Save Medical Research
 “[Myelin Repair Foundation’s] approach...could result in a promising future for big pharma, a sustainable future for the biomedical innovation ecosystem, and most importantly, a healthier future for patients.”

Forbes
Translation, Innovation, Regulation: Responding to Biopharma’s Key Challenges
 “[Myelin Repair Foundation] is basically taking the experimental medicine/translational medicine function out of pharma and running it out of an organization with an impassioned and enduring commitment to the [Valley of Death] problem.”

Businessweek
Speeding Up the Discovery of Drugs
 “Pharma produces only 20 to 30 new drugs a year. A California entrepreneur [Scott Johnson] aims to raise its output.”

Fast Company
A Look Around the Bend on the Health Innovation Highway
 “The Myelin Repair Foundation assembled its own translational lab staffed with experienced biopharma researchers to increase the odds of success for new MS treatments by ensuring academic discoveries are commercially robust and industry ready, an emphasis markedly different than funding traditional university or private company research.”

Pharmaceutical Executive
Three Ways to the Future
 “With a small $40 million budget, this professional non-profit group pursues what a labor union might call a platform of mediation: to advance a compound collaboratively, first identify the cultural and practice insecurities that attach to any relationship between industry and academia, then translate and transform these into a set of tools that end up validating the academic work—to industry standards.”

Nature Biotechnology
Patient Power
 “[Disease foundations like the MRF are] actually changing the way translational research and clinical development are done.”

Chemical and Engineering News
The New Scientists
 “Patient-driven groups... are enthusiastic about the role they can play to fill the gap between the discovery lab and the clinic. With industry becoming increasingly risk-averse, the timing is right for new models of how to do research, MRF’s Tung says. ‘This is a kind of renaissance where nonprofits are stepping up to the plate.’”

Visit our web site for the complete story on each of these selections as well as our entire news coverage.

www.myelinrepair.org

©2013 Myelin Repair Foundation. All rights reserved.